XML 15 R6.htm IDEA: XBRL DOCUMENT v3.4.0.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (24,873) $ (30,658)
Adjustments to reconcile net loss to net cash provided by (used) in operating activities:    
Depreciation and accretion 1,023 2,988
Stock-based compensation expense 1,273 2,003
Interest incurred through borrowings under Sanofi Loan Facility 1,168 33
Loss on foreign currency exchange 2,364  
Other, net 696 (7)
Changes in assets and liabilities:    
Inventory   (7,119)
Receivables from Collaboration (121) 46,154
Prepaid expenses and other current assets 1,211 3,831
Deferred product costs from collaboration   (6,251)
Other assets (86) (872)
Accounts payable (14,799) (4,182)
Accrued expenses and other current liabilities 488 (10,660)
Deferred product sales from collaboration 177 7,050
Other liabilities 721 710
Net cash provided by (used in) operating activities (30,758) 3,020
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of property and equipment (1,144) (4,203)
Proceeds from sale of property and equipment 17  
Net cash used in investing activities (1,127) (4,203)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from issuance of common stock 467 6,168
Milestone payment   (4,220)
Payment of employment taxes related to vested restricted stock units (3) (762)
Net cash provided by financing activities 464 1,186
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (31,421) 3
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 59,074 120,841
CASH AND CASH EQUIVALENTS, END OF PERIOD 27,653 120,844
SUPPLEMENTAL CASH FLOWS DISCLOSURES:    
Interest paid in cash, net of amounts capitalized 2,713 4,749
Non-cash construction in progress and property and equipment $ 558 $ 1,094